drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Oral BH3‑mimetic that selectively inhibits BCL‑2 to restore intrinsic apoptosis in malignant lymphoid cells.
nci_thesaurus_concept_id
C103147
nci_thesaurus_preferred_term
Venetoclax
nci_thesaurus_definition
An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.
drug_mesh_term
Venetoclax
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Oral
drug_mechanism_of_action
Selective, oral BH3-mimetic that inhibits BCL-2 by binding its hydrophobic groove, blocking its anti-apoptotic function and freeing pro-apoptotic effectors (e.g., BAX/BAK) to trigger intrinsic (mitochondrial) apoptosis in tumor cells; relatively spares BCL-XL.
drug_name
Venetoclax
nct_id_drug_ref
NCT06742515